Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI.
J Inherit Metab Dis
; 37(2): 277-87, 2014 Mar.
Article
en En
| MEDLINE
| ID: mdl-24108527
ABSTRACT
OBJECTIVE:
To evaluate the efficacy and safety of two dose levels of galsulfase (Naglazyme®) in infants with MPS VI. STUDYDESIGN:
This was a phase 4, multicenter, multinational, open-label, two-dose level study. Subjects were randomized 11 to receive weekly infusions of 1.0 or 2.0 mg/kg of galsulfase for a minimum of 52 weeks. Progression of skeletal dysplasia was determined by monitoring physical appearance, radiographic changes, and growth. Urinary glycosaminoglycan (GAG) levels, gross and fine motor function, cardiac function, vision, hearing, and health resource utilization were evaluated. Safety assessments were performed.RESULTS:
Four infants (aged 3.3-12.7 months) participated in the study. Galsulfase was well tolerated at 1.0 and 2.0 mg/kg/week dose levels with no drug-related serious adverse events. Two subjects experienced a total of four possible treatment-related adverse events which were all considered mild. Length and weight remained within age-expected norms. Skeletal abnormalities continued to progress in all subjects. High baseline urinary GAG levels (mean 870 µg/mg creatinine) decreased by approximately 70%; these reduced levels were maintained (mean 220 µg/mg creatinine at week 52) despite the development of anti-galsulfase antibodies. Hearing, cardiac function, hepatosplenomegaly, and facial dysmorphism stabilized or improved, but corneal clouding progressed. There was no clear difference in safety or efficacy between the two doses.CONCLUSIONS:
Galsulfase at two dose levels was safe and well tolerated in infants. Normal growth was maintained but skeletal abnormalities continued to progress. Urinary GAG levels decreased with treatment. Early initiation of galsulfase may prevent or slow progression of some disease manifestations.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Mucopolisacaridosis VI
/
N-Acetilgalactosamina-4-Sulfatasa
/
Terapia de Reemplazo Enzimático
Tipo de estudio:
Clinical_trials
Límite:
Humans
/
Infant
/
Male
Idioma:
En
Revista:
J Inherit Metab Dis
Año:
2014
Tipo del documento:
Article